Nicolas Sireau

Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment

L. Ranganath, Anna M. Milan, Andrew T. Hughes et al. · Annals of the Rheumatic Diseases · 2014 · 157 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial

L. Ranganath, Eftychia Eirini Psarelli, Jean-Baptiste Arnoux et al. · The Lancet Diabetes & Endocrinology · 2020 · 123 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Nitisinone arrests ochronosis and decreases rate of progression of Alkaptonuria: Evaluation of the effect of nitisinone in the United Kingdom National Alkaptonuria Centre

L. Ranganath, Milad Khedr, Anna M. Milan et al. · Molecular Genetics and Metabolism · 2018 · 104 citations · Full text

Medicine, Internal Medicine, Molecular Pathology +1

Twelve novel HGD gene variants identified in 99 alkaptonuria patients: focus on ‘black bone disease’ in Italy

Martina Nemethova, Ján Radvánszky, Ľudevít Kádaši et al. · European Journal of Human Genetics · 2015 · 102 citations · Full text

Medicine, Genetics, Molecular Genetics +13

Identification of alkaptonuria in the general population: a United Kingdom experience describing the challenges, possible solutions and persistent barriers

L. Ranganath, Adam Taylor, Alan Shenkin et al. · Journal of Inherited Metabolic Disease · 2011 · 46 citations

Life Sciences, Genetics, Human Genetics +3